2[2]Brew K, Dinakarpandian D, Nagase H.Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta, 2000,1477:267 - 283. 被引量：1
3[3]Stetler- Stevenson WG.The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am, 2001, 10:383- 392. 被引量：1
4[4]Sakata K, Shigemasa K, Nagai N, et al. Expression of matrix metalloproteinases (MMP- 2, MMP- 9, MT1 - MMP) and their inhibitors (TIMP -1, TIMP- 2) in common epithelial tumors of the ovary. Int J Oncol,2000, 17: 673-681. 被引量：1
5[5]Huang LW, Garrett AP, Bell DA, et al. Differential expression of matrix metalloproteinase- 9 and tissue inhibitor of metalloproteinase - 1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol, 2000 , 77:369 - 376. 被引量：1
6[6]Shigemasa K, Tanimoto H, Sakata K, et al.Induction of matrix metalloprotease- 7 is common in mucinous ovarian tumors including early stage disease. Med Oncol, 2000, 17: 52- 58. 被引量：1
7[7]Furuya M, IshikuraH, KawaradaY, et al. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Gynecol Oncol, 2000, 78: 106- 112. 被引量：1
8[8]FuruyaM, Ishikura H,.OgawaY, et al. Analyses of matrix metalloproteinsses and their inhibitors in cyst fluid of serous ovarian tumors. Pathobiology, 2000, 68: 239-244. 被引量：1
9[9]Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase- type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res, 2001, 7: 2396 - 2404. 被引量：1
10[10]Lengyel E, Schmalfeldt B, Konik E, et al. Expression of latent matrix metalloproteinase 9 ( MMP - 9) predicts survival in advanced ovarian cancer. Gynecol Oncol, 2001, 82: 291-298. 被引量：1
